Sök artiklar i SveMed+

Tidskrift

Sammanfattning

Antiviral agents such as acyclovir and penciclovir exhibit pronounced effects in virus-infected animals and cell cultures. Treatment of patients with recurrent herpes simplex labialis with these agents have however only resulted in a limited healing time reduction as the only clinical benefit. The primary infection in animal results in an extended period of virus shedding while the recurrent nature of clinical herpes labialis results in substantially shorter virus shedding duration. It has been suggested that the short virus shedding duration contribute to the limited clinical efficacy of antiviral agents and that the immune response contribute more than previously assumed. Using antiviral agents in combination with agents with immune modulating properties have recently shown improved clinical efficacy in Phase 3 setting. Phase 3 studies performed in patients with recurrent herpes simplex labialis have been reviewed.

MeSH